Quadrant Capital Group LLC Blueprint Medicines Corp Transaction History
Quadrant Capital Group LLC
- $2.65 Billion
- Q1 2025
A detailed history of Quadrant Capital Group LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Quadrant Capital Group LLC holds 3 shares of BPMC stock, worth $385. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3
Previous 3
-0.0%
Holding current value
$385
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding BPMC
# of Institutions
391Shares Held
68.5MCall Options Held
1.54MPut Options Held
1.08M-
Black Rock Inc. New York, NY6.65MShares$854 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.64MShares$853 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.42MShares$695 Million0.06% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.85MShares$494 Million5.51% of portfolio
-
Wellington Management Group LLP Boston, MA3.07MShares$395 Million0.05% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $7.67B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...